论文部分内容阅读
早就有人想通过抗体来治疗恶性肿瘤,但由于制备特异性高,且滴度高之抗体极为困难,所得的量极少,不能满足临床需要。此外,可能产生免疫增强作用,故大大限制了它的临床应用。自1975年Kohler等建立细胞融合技术以来,人们利用这种技术,产生出各种对正常细胞和肿瘤细胞表面抗原具有特异性作用的杂交瘤抗体(Hybridoma antibodies),即单克隆抗体。由于它是由持续不断增殖的肿瘤细胞所产生,故实际上能产生无限量
Someone long ago wanted to treat malignant tumors by antibodies, but because of the extremely difficult preparation of antibodies with high specificity and high titer, the amount obtained is extremely small and can not meet clinical needs. In addition, may have immune-enhancing effect, it greatly limits its clinical application. Since Kohler et al. Established the cell fusion technique in 1975, they have used this technique to generate a variety of hybridoma antibodies, ie, monoclonal antibodies, that have a specific effect on normal cells and tumor cell surface antigens. Since it is produced by a continuously proliferating tumor cell, it can in fact produce an unlimited amount